Kidney Disease News and Research

RSS

FibroGen announces proof-of-principle for FG-4592 Phase 2 study in hemodialysis patients

FibroGen, Inc., today announced proof-of-principle for oral anemia therapy FG-4592, a hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor, in end-stage renal disease patients receiving hemodialysis.

4 May 2011

New antioxidant may prevent liver damage in chronic alcoholics

An antioxidant may prevent damage to the liver caused by excessive alcohol, according to new research from the University of Alabama at Birmingham.

3 May 2011

Secondhand smoke exposure linked to high blood pressure in boys

Exposure to secondhand smoke, even at extremely low levels, is associated with increased blood pressure in boys, according to new research being presented Sunday, May 1, at the Pediatric Academic Societies annual meeting in Denver.

2 May 2011

Mediaplanet releases Kidney Health report to targeted markets in USA

On April 29, 2011, Mediaplanet Publishing released a Kidney Health report to targeted markets in USA Today. The report will be distributed to 1 million readers with contributions from Kidney Cancer Association, National Kidney Foundation, Fresenius Medical Care North America, UKidney, Medical Education Institute, and National Kidney Registry.

30 Apr 2011

Health Canada approves Eli Lilly's Cymbalta for chronic low back pain treatment

Eli Lilly Canada announced today that Health Canada has approved Cymbalta for the management of chronic low back pain.

30 Apr 2011

DVA is now DaVita Labs

Operating as a division of DaVita Inc., a leading provider of kidney care services for those diagnosed with end stage renal disease and chronic kidney disease, DVA Laboratory Services announced its new company name, DaVita Labs.

30 Apr 2011

New study identifies less invasive therapy for ACE inhibitor side-effects

A new Henry Ford Hospital study takes a closer look at one of the lesser known, but potential most serious side-effects of ACE inhibitor use - facial, tongue and airway swelling - and identifies a successful and less invasive course of treatment.

29 Apr 2011

Flu vaccination lowers kidney transplant recipients' risk of organ loss and death

Getting vaccinated against the flu lowers kidney transplant recipients' risk of organ loss and death, according to a study appearing in an upcoming issue of the Clinical Journal of the American Society Nephrology.

29 Apr 2011

Takeda, Affymax announce additional peginesatide Phase 3 study results in dialysis patients

Affymax, Inc. and Takeda Pharmaceutical Company Limited, today announced results of additional analyses from two Phase 3 studies of the investigational agent, peginesatide in chronic renal failure patients on dialysis with anemia.

29 Apr 2011

GHRI founder earns Baxter-AUPHA recognition for Health Services Research

In recognition of his significant contributions to studying how best to provide health care, Edward H. Wagner, MD, MPH, has been named the 2011 recipient of the William B. Graham Prize for Health Services Research.

From Baxter International Inc. 29 Apr 2011

Ramipril can effectively reduce risk of ESRD in obese patients

The angiotensin-converting enzyme inhibitor drug, ramipril, is particularly effective in lowering the risk of end-stage renal disease in obese patients, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology.

29 Apr 2011

New discoveries on polycystin-1 can lead to novel kidney disease treatment

Two discoveries at UC Santa Barbara point to potential new drug therapies for patients with kidney disease. The findings are published in this week's issue of the Proceedings of the National Academy of Sciences.

27 Apr 2011

ACC/AHA release consensus document to help clinicians reduce risk of hypertension in older adults

Hypertension is very common among older adults. 64 percent of older men and 78 percent of older women have high blood pressure, placing them at heightened risk for heart disease including heart failure, stroke, coronary artery disease and atrial fibrillation, as well as chronic kidney disease and diabetes mellitus.

26 Apr 2011

PVT1 gene may help reduce diabetic nephropathy

A gene called PVT1 may help reduce the kidneys ability to filter blood, leading to kidney disease, kidney failure and death, according to a study published today by researchers at the Translational Genomics Research Institute.

25 Apr 2011

Studies emphasize need to avoid central venous catheters in patients on hemodialysis

Patients on peritoneal dialysis (PD) typically have a higher early survival rate than patients on hemodialysis (HD). New data suggest that this difference may be explained by a higher risk of early deaths among patients undergoing HD with central venous catheters, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN).

22 Apr 2011

JASN publishes positive results from pirfenidone study in diabetic nephropathy

Researchers at the University of California, San Diego School of Medicine, the National Institutes of Health and the Mayo Clinic have published promising results of a clinical study using an experimental anti-fibrotic and anti-inflammatory drug called pirfenidone to treat patients with diabetic nephropathy. Their study will be published in the April 21 issue of the Journal of the American Society of Nephrology.

22 Apr 2011

Elderly individuals with CKD more likely to suffer from heart disease

Chronic kidney disease is common and linked with heart disease in the very elderly, according to a study appearing in an upcoming issue of the Clinical Journal of the American Society Nephrology.

22 Apr 2011

Amgen, UCB report positive results from AMG 785/CDP7851 comparative Phase 2 study for postmenopausal osteoporosis

Amgen and UCB announced today positive top-line results from their Phase 2 clinical study comparing sclerostin-antibody AMG 785/CDP7851 to placebo in postmenopausal women with low bone mineral density (BMD) for the treatment of postmenopausal osteoporosis (PMO).

21 Apr 2011

Intrinsic Bioprobes launches mass spectrometry-based protein assays for in-vitro diagnostic testing

Intrinsic Bioprobes Inc. ("IBI") today announced the launch of its first mass spectrometry-based protein assays for in-vitro diagnostic testing. The assays for beta-2-microglobulin, cystatin C, and retinol binding protein are performed on IBI's MASSAY® platform at the CLIA-certified and College of American Pathology (CAP) accredited diagnostic laboratory of the Institute of Genomics Medicine, UMDNJ-New Jersey Medical School.

20 Apr 2011

Ampio raises $12.732 million through private placement of common stock

Ampio Pharmaceuticals, Inc. announced today the successful completion of a private placement from which Ampio received gross proceeds of $12.732 million.

20 Apr 2011